

Please try another search
(Reuters) - The U.S. Centers for Disease Control and Prevention (CDC) on Friday expanded the use of COVID-19 vaccines that target both the original coronavirus and Omicron sub-variants to include children aged 6 months through 5 years.
The development comes a day after the U.S. Food and Drug Administration authorized the updated shots from Moderna (NASDAQ:MRNA) as well as Pfizer (NYSE:PFE) and its partner BioNTech for use in children as young as 6 months.
Children aged 6 months through 5 years will now be eligible to get a Moderna bivalent booster 2 months after their final primary vaccination dose for COVID-19.
Pfizer/BioNTech's updated vaccine for children aged 6 months through 4 years can be given only as the third dose for those who are yet to complete their primary COVID-19 vaccinations.
Vaccines for young children in the United States were only approved in June this year, making them the last group to become eligible for vaccination.
Data from the CDC shows only 2.9% children under the age of 2 years, and less than 5% of children aged 2 to 4 years, who are eligible have completed their primary vaccination series as of Dec. 7.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.